PER-099-03已完成未知
RANDOMIZED STUDY OF PHASE II / III OF PACLITAXEL + CARBOPLATINO WITH OR WITHOUT BEVACIZUMAB IN PATIENTS WITH ADVANCED PULMON CANCER OR METASTASIC NO SCAMOSO NSCLC.
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),0 个研究点目标入组 0 人开始时间: 2004年2月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •not contemplated
排除标准
- •not contemplated
研究者
相似试验
进行中（未招募）
1 期
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.MedDRA version: 18.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864Metastatic Breast CancerEUCTR2012-003262-41-GBGenentech, Inc.179
进行中（未招募）
1 期
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.MedDRA version: 15.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic Breast CancerEUCTR2012-003262-41-ESGenentech, Inc.180
进行中（未招募）
1 期
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.Metastatic Breast CancerEUCTR2012-003262-41-BEGenentech, Inc.180
进行中（未招募）
1 期
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.MedDRA version: 19.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic Breast CancerEUCTR2012-003262-41-CZGenentech, Inc.180
进行中（未招募）
1 期
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.Metastatic Breast CancerEUCTR2012-003262-41-ATGenentech, Inc.180